MWA
CBPO

Marshall Wace Asia’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Marshall Wace Asia’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,344
Closed -$2.48M – 197
2020
Q3 		$2.48M Buy
+22,344
New +$2.4M 0.06% 87
2020
Q1 		– Sell
-1,181
Closed -$137K – 207
2019
Q4 		$137K Sell
1,181
-5,450
-82% -$631K ﹤0.01% 112
2019
Q3 		$759K Buy
+6,631
New +$659K 0.02% 93

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Marshall Wace Asia's CBPO Position: Q4 2020 in Review

Marshall Wace Asia sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2020, closing a stake of 22,344 shares — an estimated $2.48M sold.

Marshall Wace Asia first reported a position in CBPO in Q3 2019 and held it in 3 quarters. The position peaked at $2.48M in Q3 2020. 89 funds tracked by Wall St. Rank hold CBPO as of Q4 2020.

  • Marshall Wace Asia reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace Asia sold 22,344 China Biologic Products Holdings, Inc. shares in Q4 2020, an estimated $2.48M.
  • Marshall Wace Asia first reported a position in China Biologic Products Holdings, Inc. in Q3 2019 and held it in 3 quarters.
  • Marshall Wace Asia's China Biologic Products Holdings, Inc. position peaked at $2.48M in Q3 2020.
  • 89 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2020.

Based on Marshall Wace Asia's 13F filing for Q4 2020, filed 16 Feb 2021.